Treatment of subclinical hyperthyroidism in patients older than 50 years: A randomized controlled study.
in European Thyroid JournalSearch for other papers by Bernard Goichot in
Current site
Google Scholar
PubMed
Search for other papers by François Lefebvre in
Current site
Google Scholar
PubMed
Search for other papers by Stéphane Vinzio in
Current site
Google Scholar
PubMed
Search for other papers by Anne Cailleux in
Current site
Google Scholar
PubMed
Search for other papers by Jean-Marc Kuhn in
Current site
Google Scholar
PubMed
Search for other papers by Olivier Schneegans in
Current site
Google Scholar
PubMed
Search for other papers by Bodgan Catargi in
Current site
Google Scholar
PubMed
Search for other papers by Olivier Gilly in
Current site
Google Scholar
PubMed
Search for other papers by Philippe Baltzinger in
Current site
Google Scholar
PubMed
Search for other papers by Nicolas Meyer in
Current site
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Current site
Google Scholar
PubMed
Objective: Subclinical hyperthyroidism (SCH) is common and associated with atrial fibrillation (AF) risk in the elderly. Current guidelines rely on a low level of evidence.
Methods: Randomized clinical trial including patients 50 years and older, with TSH <0.4 mU/L and normal thyroid hormone concentrations. All patients showed autonomy on thyroid scan. They were randomized either to receive radioiodine (I131) or to be monitored and treated only if they underwent AF or evolved towards overt hyperthyroidism. Primary outcome was the onset of new AF. Secondary outcomes were treatment-induced hypothyroidism rate and health-related quality of life.
Results: 144 patients (mean age 65.3±8.9y, 76% female) were randomized, 74 to surveillance and 70 to treatment. Four patients in the surveillance group and one in the treatment group developed AF (p=0.238). However, the patient who developed AF in the treatment group maintained TSH <0.4 mU/L at AF onset. A post-hoc analysis was carried out and showed that when normalization of TSH was considered, the risk of AF was significantly reduced (p=0.0003). In the surveillance group, several patients showed no classical characteristics associated with AF risk, including age>65y or TSH<0.1mU/L. Of 94 patients treated using radioiodine, 25% developed hypothyroidism during follow-up.
Conclusions: Due to recruitment difficulties this study failed to demonstrate that SCH treatment can reduce significantly the incidence of AF in patients older than 50 years with thyroid autonomy even if all the patients who developed AF maintained TSH <0.4 mU/L. This result must be balanced with the increased risk of radioiodine-induced hypothyroidism.
European Thyroid Journal is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
As an open-access journal, European Thyroid Journal articles are immediately available to read on publication, without restriction. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Jan 2022 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 237 | 237 | 68 |
| PDF Downloads | 292 | 292 | 82 |
Online ISSN: 2235-0802
Print ISSN: 2235-0640
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519